Key GI Journal Articles - Pancreatic Metastatic
Published: Wed Jun 1, 2011 Updated:Fri Oct 14, 2011
-
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
ME Pavel et al, The Lancet, Volume 378, Issue 9808, Pages 2005 - 2012, 10 December 2011
-
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
T Conroy et al, NEJM. May 12 2011; 364:1817-25
-
Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
PA Philip et al, JCO. Aug 1 2010; 28(22):3605-3610
-
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
HL Kindler et al, JCO. Aug 1 2010; 28(22):3617-3622
-
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
D Cunningham et al, JCO Early Release. Oct 26 2009 (ahead of print)
